SITAGLIPTIN
| Brand name | ZITUVIO |
|---|---|
| Active ingredient | SITAGLIPTIN |
| Strength | 25MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | October 2023 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10925871 | February 2035 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.